title: Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis.
abstract: OBJECTIVE
  Quantitative data on subsequent cancers after primary cancers provide information on treatment-related risks on second cancers, with implications for therapeutic adverse effects and human susceptibility in general. Quantitative data on solid tumors are limited. We focus on survivors of non-Hodgkin's lymphoma (NHL) because the disease is diagnosed at a wide range of ages and treated uniformly primarily with chemotherapy.
  
  
  METHODS
  The nationwide Swedish Family-Cancer Database included 11.5 million individuals whose cancers were retrieved from the Swedish Cancer Registry. Standardized incidence ratios (SIRs) were calculated for subsequent neoplasms among 28,131 patients with NHL.
  
  
  RESULTS
  The SIR for solid tumors after NHL was 1.65 (2,290 patients) and that for lymphohematopoietic neoplasms was 5.36 (369 patients). Among the 25 most common solid tumors, the SIRs were increased for all but nine sites; the highest SIR (40.8) was observed for spinal meningioma. The SIRs for solid tumors declined in an age-dependent manner from 4.52 in diagnostic age younger than 20 years to 1.12 in diagnostic age 70+ years. In the most common patient groups, the SIRs for solid tumors increased up to 30 years after NHL diagnosis. Because of the high incidence of solid tumors in these age groups, they contributed the largest numbers of therapy-related cases.
  
  
  CONCLUSIONS
  These data indicate that age at treatment determines both the magnitude of the initial relative risk and the time-dependent modulation of the response. Therapy-related damage persists at least 30 years and its toll of solid tumors is largest 21 to 30 years after diagnosis.
authors.affiliation: Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Im Neuenheimer Feld 580, Heidelberg, Germany. k.hemminki@dkfz.de
authors.forename: Kari
authors.initials: K
authors.lastname: Hemminki
authors.forename: Per
authors.initials: P
authors.lastname: Lenner
authors.forename: Jan
authors.initials: J
authors.lastname: Sundquist
authors.forename: Justo Lorenzo
authors.initials: JL
authors.lastname: Bermejo
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D000375:Aging; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000453:epidemiology*; D008297:Male; D008579:Meningioma / Q000175:diagnosis / Q000453:epidemiology; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology*; D016609:Neoplasms, Second Primary / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology*; D012042:Registries; D018570:Risk Assessment; D017678:Sex Distribution; D013125:Spinal Neoplasms / Q000175:diagnosis / Q000453:epidemiology; D013548:Sweden / Q000453:epidemiology